Molecules with specificity for cd45 and cd79

Abstract

The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.

1 - 33 . (canceled) 
     
     
         34 . An antibody comprising a binding domain specific to antigen CD45 and a binding domain specific to antigen CD79b,
 wherein the binding domain specific to the antigen CD45 comprises:   3 heavy chain CDRs comprising SEQ ID NO: 128 for CDRH1, SEQ ID NO: 129 for CDRH2 and SEQ ID NO: 130 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 125 for CDRL1, SEQ ID NO: 126 for CDRL2 and SEQ ID NO: 127 for CDRL3;   wherein the binding domain specific to the antigen CD79b comprises:   3 heavy chain CDRs comprising SEQ ID NO: 88 for CDRH1, SEQ ID NO: 89 for CDRH2 and SEQ ID NO: 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO: 85 for CDRL1, SEQ ID NO: 86 for CDRL2 and SEQ ID NO: 87, or a derivative thereof, for CDRL3   wherein, in at least one CDR (a) at least one cysteine residue has been substituted with another amino acid, (b) at least one aspartic acid isomerisation site has been removed by substituting at least one amino acid, (c) at least one asparagine deamidation site has been removed by substituting at least one amino acid, (d) at least one glycosylation site has been removed by substituting at least one amino acid, or (e) a combination thereof.